Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CAMKK1 | Q8N5S9 | 4/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28239738 | 0.89 | SLC6A2 (0.48) | KEAP1PTGDR2L3MBTL1CAMKK2 | |
| SCHEMBL1334357 | 0.87 | HPGD (0.46) | KEAP1PTGDR2L3MBTL1CES2CES1 | |
| SCHEMBL7025132 | 0.87 | CA1 (0.47) | KEAP1PTGDR2L3MBTL1NOTUMCES2 | |
| SCHEMBL7025130 | 0.87 | CA1 (0.47) | KEAP1PTGDR2L3MBTL1NOTUMCES2 | |
| SCHEMBL31237037 | 0.85 | KEAP1 (0.52) | KEAP1PTGDR2L3MBTL1NOTUMCES2 | |
| SCHEMBL5837226 | 0.84 | PTGDR2 (0.40) | KEAP1PTGDR2CAMKK2NOTUMCAMKK1 | |
| SCHEMBL5836884 | 0.84 | PTGDR2 (0.40) | KEAP1PTGDR2CAMKK2NOTUMCAMKK1 | |
| SCHEMBL1740214 | 0.84 | PTGDR2 (0.42) | PTGDR2L3MBTL1CES2CES1HPGD | |
| SCHEMBL17682015 | 0.84 | PTGDR2 (0.42) | PTGDR2L3MBTL1CES2CES1HPGD | |
| SCHEMBL5837468 | 0.82 | CYP2C9 (0.41) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9732077-B2 | Diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2016085784-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085784-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085783-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085783-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305916-A1 | METHYL DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | KEAP1 478/4885PTGDR2 365/4885L3MBTL1 4048/4885 |
| US-20160318923-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | KEAP1 328/4885PTGDR2 335/4885L3MBTL1 4704/4885 |
| US-10000499-B2 | Methyl diazepane orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | KEAP1 478/4885PTGDR2 365/4885L3MBTL1 4048/4885 |
| US-20170320876-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | KEAP1 304/4885PTGDR2 302/4885L3MBTL1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.